Regulatory Focus™ > News Articles > EDQM Continuing Development of New, Comprehensive Anti-Counterfeiting Strategy

EDQM Continuing Development of New, Comprehensive Anti-Counterfeiting Strategy

Posted 18 April 2012 | By

The European Directorate for Quality in Medicines and Healthcare (EDQM), the Council of Europe's (EC) pharmaceutical standards body, announced it is continuing to develop and expand a new anti-counterfeiting strategy it says will reduce pharmaceutical-related crime.

In its 18 April announcement, EDQM said the multi-layer legislative strategy aims to increase, among other things, training for inspection officials from EC member states, increased inspection and testing activities, traceability through mass serialization and the establishment of a Unique Medicine Identifier, better coordination between customs authorities and regulatory authorities, and patient verification systems.

The comprehensive strategy, outlined on EDQM's website, is being dubbed the eTACT drug traceability system.

The eTACT system is currently restricted to the traceability of secondary packaging and available to all member states of the European Pharmacopoeia, EDQM said in a statement.


Read more:

EDQM - THE EDQM PROGRESSES WITH eTACT, ITS PATIENT-ORIENTED TRACEABILITY SERVICE FOR MEDICINES

EDQM - The EDQM anti-counterfeiting strategy

Securing Pharma - EDQM showcases eTACT traceability system


Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe